AYUSH OR AYUS? when Systems are overlooked, it is the common man who loses

Dr Shivang Swaminarayan

The ongoing practice of using the term “AYUSH” as a generic substitute for Ayurveda, without clear system-wise representation, may appear administrative or semantic. In reality, it carries far deeper consequences—not for any medical system, but for the Common Man of Bharat.

For millions of Indians living beyond metros and district headquarters—particularly at the taluka and village levels—the availability of MBBS doctors remains severely limited. In these very geographies, homoeopathy has quietly and consistently filled the healthcare vacuum. Qualified homoeopathic physicians are often the first point of care, delivering safe, affordable, and accessible treatment for acute illnesses, chronic diseases, women’s and child health issues, geriatric care, and lifestyle disorders.

Homoeopathy has reached the unreached, not through policy slogans but through decades of grassroots presence. It has done so without expensive infrastructure, without dependence on high-end diagnostics, and without imposing catastrophic out-of-pocket expenditure on families already under economic stress.

When policy narratives, official communications, and international representations fail to explicitly acknowledge homoeopathy’s role—and instead subsume AYUSH into an Ayurveda-centric discourse—the real casualty is public choice. The Common Man is deprived of informed access to a system of medicine that is:

• Affordable
• Widely available beyond taluka level
• Backed by qualified, regulated professionals
• Trusted by over 50 crore citizens

Healthcare equity is not achieved by invisible systems that are working on the ground. It is achieved by recognising, strengthening, and integrating all available resources in a transparent manner. Homoeopathy is not an alternative at the margins; for vast sections of Bharat, it is mainstream healthcare.

India’s healthcare challenge is not the coexistence of multiple systems—it is the non-availability of care where it is most needed. Any policy approach that overlooks homoeopathy, even inadvertently, risks weakening one of the most accessible healthcare lifelines for rural and semi-urban India.

This is not a plea for professional recognition. It is a reminder that when homoeopathy is sidelined in policy and communication, the Common Man is sidelined in healthcare.

A truly inclusive AYUSH vision must therefore reflect ground realities, not just institutional prominence—because healthcare systems exist not for themselves, but for the people they serve.

Homoeopathy’s stagnation is not solely due to external resistance; it also reflects internal strategic deficits.

1. Key Structural Gaps
2. Fragmented Leadership and Voice
3. No unified national or global Homoeopathy policy consortium speaks with authority and coherence.
4. Weak Research Architecture
5. Predominantly small, isolated studies with limited multicentric, translational, or outcome-driven designs.
6. Minimal Industry–Academia–Clinician Linkages
7. Lack of robust collaboration between manufacturers, practitioners, research institutes, and technology partners.
8. Absence from Innovation & Startup Ecosystems
9. Homoeopathy has not positioned itself as a health-tech or bio-innovation domain.
10. Poor Economic Narrative
11. Homoeopathy is discussed as “low cost” but not as a cost-saving public health investment.
12. Reactive Rather than Proactive Policy Engagement
13. Advocacy remains defensive, not agenda-setting.

Strategic Pathways to Mainstreaming

1. Reframe Homoeopathy as a Public Health Solution

• Position Homoeopathy in chronic disease management, multimorbidity, geriatrics, mental health, allergies, and NCDs.
• Generate Health Technology Assessment (HTA) data: cost per patient, reduction in drug burden, hospitalization avoidance etc.

2. Build Flagship National Research Programs

• Multicentric pragmatic trials.
• Real-world evidence registries.
• Practice-Based Research Networks (PBRN).
• Integration of AI, data science, and biostatistics.

3. Create a Homoeopathy Innovation & Entrepreneurship Mission

Support startups in:

• Standardisation technologies
• Potentisation instrumentation
• Nano-characterisation
• Digital case management
• Tele-homoeopathy platforms

4. Establish Centres of Integrative Clinical Excellence

• Co-located Homoeopathy services within medical colleges, district hospitals, and wellness centres.
• Demonstration models rather than debates.

5. Strengthen Industry Engagement

• Incentivise R&D investment.
• Encourage public–private research partnerships.
• Export-oriented product development.

6. Professionalise Policy Advocacy

• Dedicated policy cells.
• White papers, economic impact reports, and parliamentary briefs.
• Continuous engagement, not episodic representation.

III. Active Policy Brief:

Priority Asks

• Declare Homoeopathy a National Public Health Research Priority Area.
• Allocate a dedicated Homoeopathy Research & Innovation Fund.
• Integrate Homoeopathy services in national programs for NCDs, mental health, geriatric care, and palliative care.
• Include Homoeopathy startups under national incubation and deep-tech schemes.
• Mandate outcome reporting from government Homoeopathy institutions.
• Establish a National Homoeopathy Data Grid.
• Ensure proportional representation of Homoeopathy within WHO-GCTM collaborative projects.

The Central Question

“Is Homoeopathy merely a victim of external suppression—or has it failed to evolve its institutional, scientific, economic, and policy strategies in step with changing global realities?”

Other Indian-origin sectors—IT, Telecom, Biotech, BPO/KPO—built credibility through performance, scalability, and measurable impact, often before receiving policy patronage. Homoeopathy must follow a similar trajectory.

Key Take Away:
The era of expecting acceptance based solely on historical legacy or moral correctness is over. Homoeopathy now stands at a decisive inflection point:

Either it transforms into an evidence-generating, economically relevant, innovation-driven health sector –  or it risks permanent marginalisation.

This is the moment for strategic courage, institutional reinvention, and collective accountability—before inaction becomes irreversible.

Dr Shivang Swaminarayan
(Gujarat, India)
Email : shivang.swaminarayan@gmail.com